Exploring a new boron-based treatment for kidney cancer
Official title: Assessment of a recently developed boron-based HIF inhibitor as a prospective therapy for renal cell carcinoma (RCC)
Funded at University of Missouri Kansas City · NIH-10947752 · Data updated 2026-11-12
This study is looking at a new treatment that could help people with clear cell kidney cancer by blocking a specific pathway that makes the cancer grow, and they're testing different versions of a compound to find the best one for this purpose.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri Kansas City NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | August 7, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $396,061 |
| NIH project number | 1R21CA292298-01 |
| Project ID | NIH-10947752 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma, particularly those with advanced disease.
✕Less likely to help
Patients with other types of kidney cancer or those who are not eligible for experimental therapies may not benefit from this research.
What this research studies
This research investigates a novel boron-based inhibitor that targets the hypoxia-inducible factor (HIF) pathway, which is often overactive in clear cell renal cell carcinoma (RCC). By understanding how this inhibitor works and its effects on cancer cells, the researchers aim to develop a more effective therapy for RCC. The study involves testing various analogs of a compound called honokiol to see which ones best inhibit the HIF pathway and evaluating their effectiveness in a mouse model of RCC. If successful, this could lead to new treatment options for patients with this type of kidney cancer.
Why it matters
Potential benefit: If successful, this research could provide a new and effective therapy for patients suffering from renal cell carcinoma.
How similar studies have gone: Previous research has shown promise in targeting the HIF pathway for cancer treatment, indicating that this approach could be effective.
Where this research is happening
-
University of Missouri Kansas City
Kansas City, United States Active
Researchers
- Principal investigator: Mukherji, Mridul — University of Missouri Kansas City
- Study coordinator: Mukherji, Mridul
Related research
Other NIH-funded projects on the same topics.
-
Improving kidney cancer treatment by enhancing immune response
This study is looking at how to help your immune system better fight kidney cancer by understanding a protein that helps cancer cells survive, with the hope of improving current treatments for patients like you.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.